(Total Views: 978)
Posted On: 03/25/2022 9:45:17 AM
Post# of 148899
Re: KenChowder #120647
Great Nash results will do nothing for our current value. There has been so many different drugs that have had great phase 2 results and failed phase 3 for Nash that unless proven at phase 3 we will get no credit for value in my opinion.
One thing that is for sure is we have mTNBC results equal to or maybe even better ( if we re-analyzed our results) than the standard of care of Trodelvey. This is huge for our value to start us out in cancer treatments of solid tumors and possibly more. Cancer is a given now for us now to look forward to. Let’s get the BTD filed again after re-analysis of our 28 patients done… if we haven’t already…
Our benefits in combo therapy for HIV is not lucrative as it once was because of the limitations of use reduced to a third option treatment after the HIV patients have had resistance to two or more Hartt drugs and all the other drugs on the market the past few years.
Mono HIV therapy should open up our HIV market with no restrictions for drug resistance if we bargain that and that’s where the money and advantage comes in. Not only does Leronlimab put HIV in check… it has beneifits other drugs do not. Like possible liver benefits from reduction NAFLD and Nash which we need to prove out still but shows great promise. No resistance shown in anyone using Leronlimab. No list of bad side effects like the rest of the market drugs for HIV. I personally see a market domination because of the no side effects and only more possible good benefits that Leronlimab provides. Who would not like what Leronlimab has to offer? We know there are many more benefits that a regular regimen of Leronlimab with reduced inflammation benefits will give the user like a reduction in possible solid tumor cancer and 89 more possible disease on ohm’s list. This makes Leronlimab way more attractive than the rest of the HIV market drugs in my opinion. I don’t have HIV but I hope some day to be a person that takes Leronlimab for the benefits of reduced inflammation of arthritis or any of the 90 other issues that could happen as we age.
This is why I personally don’t believe that we are in buy-out or partnership talks right now. Think about it. If Nader could NOT raise the stock price because nobody believed in him anymore. Do you think a Pharma would believe in him and Leronlimab? We still need results from a phase 3 for Nash or any other indication before we are looked at seriously by anyone. HIV alone will not perk the interest of big Pharma with our market value reduction to what Nader said was probably now just 30 million annually. Which was 3-5 billion just two short years ago for the same Combo HIV approval. Other drugs have reduced our market possibilities for HIV combo.
We may need to slow trials down to a crawl to afford what we have in shares to sell for operating costs. If we are lucky enough to have a quick approval in something like mTNBC or even a EUA in Covid critical then our whole world changes. Our value will be immensely changed and life will be good for us all. We most definitely have this as a possibility and this is my biggest hope. The lack of communication from Cytodyn is just the way our future is going to be. Nobody will give as much PR as Nader and we just need to get use to that.
We have a lot to look forward to and we need a quick approval this year and in my opinion we have a great chance in HIV combo and mTNBC and Covid critical. These 3 indications will get us a value jump and set things straight for our future. I believe 2022 is the year of approvals and maybe we get all 3 approvals. Then big Pharma will be offering or maybe we don’t accept their offers because they can’t afford us? We will see and the future will only show us what we hope and we hope for great things. I know I do. I am still a believer in a life changing drug called Leronlimab. I have never sold a share. Our time is getting closer and closer in my opinion…
One thing that is for sure is we have mTNBC results equal to or maybe even better ( if we re-analyzed our results) than the standard of care of Trodelvey. This is huge for our value to start us out in cancer treatments of solid tumors and possibly more. Cancer is a given now for us now to look forward to. Let’s get the BTD filed again after re-analysis of our 28 patients done… if we haven’t already…
Our benefits in combo therapy for HIV is not lucrative as it once was because of the limitations of use reduced to a third option treatment after the HIV patients have had resistance to two or more Hartt drugs and all the other drugs on the market the past few years.
Mono HIV therapy should open up our HIV market with no restrictions for drug resistance if we bargain that and that’s where the money and advantage comes in. Not only does Leronlimab put HIV in check… it has beneifits other drugs do not. Like possible liver benefits from reduction NAFLD and Nash which we need to prove out still but shows great promise. No resistance shown in anyone using Leronlimab. No list of bad side effects like the rest of the market drugs for HIV. I personally see a market domination because of the no side effects and only more possible good benefits that Leronlimab provides. Who would not like what Leronlimab has to offer? We know there are many more benefits that a regular regimen of Leronlimab with reduced inflammation benefits will give the user like a reduction in possible solid tumor cancer and 89 more possible disease on ohm’s list. This makes Leronlimab way more attractive than the rest of the HIV market drugs in my opinion. I don’t have HIV but I hope some day to be a person that takes Leronlimab for the benefits of reduced inflammation of arthritis or any of the 90 other issues that could happen as we age.
This is why I personally don’t believe that we are in buy-out or partnership talks right now. Think about it. If Nader could NOT raise the stock price because nobody believed in him anymore. Do you think a Pharma would believe in him and Leronlimab? We still need results from a phase 3 for Nash or any other indication before we are looked at seriously by anyone. HIV alone will not perk the interest of big Pharma with our market value reduction to what Nader said was probably now just 30 million annually. Which was 3-5 billion just two short years ago for the same Combo HIV approval. Other drugs have reduced our market possibilities for HIV combo.
We may need to slow trials down to a crawl to afford what we have in shares to sell for operating costs. If we are lucky enough to have a quick approval in something like mTNBC or even a EUA in Covid critical then our whole world changes. Our value will be immensely changed and life will be good for us all. We most definitely have this as a possibility and this is my biggest hope. The lack of communication from Cytodyn is just the way our future is going to be. Nobody will give as much PR as Nader and we just need to get use to that.
We have a lot to look forward to and we need a quick approval this year and in my opinion we have a great chance in HIV combo and mTNBC and Covid critical. These 3 indications will get us a value jump and set things straight for our future. I believe 2022 is the year of approvals and maybe we get all 3 approvals. Then big Pharma will be offering or maybe we don’t accept their offers because they can’t afford us? We will see and the future will only show us what we hope and we hope for great things. I know I do. I am still a believer in a life changing drug called Leronlimab. I have never sold a share. Our time is getting closer and closer in my opinion…
(7)
(2)Scroll down for more posts ▼
